medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2016, Number 3

<< Back Next >>

Biotecnol Apl 2016; 33 (3)

The role of promoter DNA methylation of six cancer-associated miRNA genes in ovarian cancer development and progression

Loginov VI, Burdennyy AM, Pronina IV, Filippova EA, Kazubskaya TP, Braga EA

Language: English
References: 25
Page: 3211-3215
PDF size: 317.88 Kb.


ABSTRACT

DNA methylation of promoter CpG islands and interactions between microRNAs and messenger RNAs of target genes are considered two crucial mechanisms for gene and pathway deregulation in malignant tumors. Methylation was analyzed for the large group of tumor-suppressor microRNA genes in various malignancies, but in ovarian tumors, it was not studied extensively yet. Our goal was to identify novel microRNA genes with aberrant methylation in epithelial ovarian cancer and assess contribution of promoter methylation of these genes to ovarian cancer development and progression. Therefore, DNA methylation of six microRNA genes (MIR-9-1, MIR-9-3, MIR-132, MIR-148a, MIR-191, MIR-212) was analyzed using a representative set of 54 paired (tumor/normal) ovarian tissue samples and methylation-specific PCR. The methylation frequencies of four of the examined genes (MIR-9-1, MIR-9-3, MIR-132, MIR-148a) were significantly higher in tumor samples in comparison with matched histologically normal samples: 20-57 % vs 4-9 % (p ≤ 0.01, Fisher’s exact test). Conversely, hypomethylation was revealed for MIR-191: 13 % vs 59 %, p ≤ 0.01. We showed strong association of MIR-9-1 and MIR-9-3 hypermethylation with advanced III/IV clinical stages, low differentiation, high tumor sizes (p ≤ 0.05), and the presence of lymph node metastases on the level of a trend. Besides, we observed the dependence of MIR-191 hypomethylation on the ovarian tumor cell differentiation (p ≤ 0.05). Thus, our findings provide the evidence on the considerable contribution of aberrant methylation of five microRNA genes to ovarian cancer development and progression, and allow us to suggest novel potential biomarkers.


REFERENCES

  1. Engelberth SA, Hempel N, Bergkvist M. Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics. Crit Rev Oncog. 2014;19(3-4): 281-315.

  2. Kinose Y, Sawada K, Nakamura K, Kimura T. The role of microRNAs in ovarian cancer. Biomed Res Int. 2014;2014: 249393.

  3. Coward JI, Middleton K, Murphy F. New perspectives on targeted therapy in ovarian cancer. Int J Womens Health. 2015;7: 189-203.

  4. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7): 484-92.

  5. Kunej T, Godnic I, Ferdin J, Horvat S, Dovc P, Calin GA. Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat Res. 2011;717(1-2): 77-84.

  6. Loginov VI, Rykov SV, Fridman MV, Braga EA. Methylation of miRNA genes and oncogenesis. Biochemistry (Mosc). 2015;80(2):145-62.

  7. Piletic K, Kunej T. MicroRNA epigenetic signatures in human disease. Arch Toxicol. 2016;90(10):2405-19.

  8. Baylin SB, Jones PA. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol. 2016;8(9):a019505.

  9. Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L, et al. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol. 2012;124(2):325-34.

  10. Li X, Pan Q, Wan X, Mao Y, Lu W, Xie X, et al. Methylation-associated HasmiR- 9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma. BMC Cancer. 2015;15:509.

  11. Schmid G, Notaro S, Reimer D, Abdel- Azim S, Duggan-Peer M, Holly J, et al. Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer. BMC Cancer. 2016;16:102.

  12. Zuberi M, Khan I, Mir R, Gandhi G, Ray PC, Saxena A. Utility of serum miR-125b as a diagnostic and prognostic indicator and its alliance with a panel of tumor suppressor genes in epithelial ovarian cancer. PLoS One. 2016;11(4):e0153902.

  13. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects [Internet]. Ferney-Voltaire: World Medical Association, Inc.; 2013 [cited 2016 Oct 11]. Available from: http://www. wma.net/en/30publications/10policies/b3/.

  14. Sobin L.H. and Wittekind C. TNM Classification of Malignant Tumours, 6th edition. New York: Wiley; 2002.

  15. Tavassoli FA, Devilee P. World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.

  16. Pronina IV, Loginov VI, Burdennyy AM, Fridman MV, Kazubskaya TP, Dmitriev AA, et al. Expression and DNA methylation alterations of seven cancer-associated 3p genes and their predicted regulator miRNAs (miR-129-2, miR-9-1) in breast and ovarian cancers. Gene. 2016;576(1 Pt 3):483-91.

  17. Loginov VI, Burdennyy AM, Pronina IV, Khokonova VV, Kurevljov SV, Kazubskaya TP, et al. Novel miRNA genes hypermethylated in breast cancer. Mol Biol (Mosk). 2016;50(5):797-802.

  18. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A. 2008;105(36):13556-61.

  19. Vrba L, Munoz-Rodriguez JL, Stampfer MR, Futscher BW. miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PLoS One. 2013;8(1):e54398.

  20. Tian H, Hou L, Xiong YM, Huang JX, Zhang WH, Pan YY, et al. miR-132 targeting E2F5 suppresses cell proliferation, invasion, migration in ovarian cancer cells. Am J Transl Res. 2016;8(3):1492-501.

  21. Gong L, Wang C, Gao Y, Wang J. Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis. Biomed Pharmacother. 2016; 83:58-63.

  22. Wei LQ, Liang HT, Qin DC, Jin HF, Zhao Y, She MC. MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF. Tumour Biol. 2014;35(12):12427-34.

  23. Dong M, Yang P, Hua F. MiR-191 modulates malignant transformation of endometriosis through regulating TIMP3. Med Sci Monit. 2015;21:915-20.

  24. Yanaihara N, Noguchi Y, Saito M, Takenaka M, Takakura S, Yamada K, et al. MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma. PLoS One. 2016;11(9):e0162584.

  25. Incoronato M, Urso L, Portela A, Laukkanen MO, Soini Y, Quintavalle C, et al. Epigenetic regulation of miR-212 expression in lung cancer. PLoS One. 2011;6(11):e27722.




2020     |     www.medigraphic.com